FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.
Sow HS, Benonisson H, Breukel C, Visser R, Verhagen OJHM, Bentlage AEH, Brouwers C, Claassens JWC, Linssen MM, Camps M, van Hall T, Ossendorp F, Fransen MF, Vidarsson G, Verbeek JS.
Sow HS, et al. Among authors: fransen mf.
Int J Cancer. 2019 Jan 15;144(2):345-354. doi: 10.1002/ijc.31899. Epub 2018 Nov 12.
Int J Cancer. 2019.
PMID: 30259976
Free article.